182 related articles for article (PubMed ID: 33958279)
1. Clinical characteristics of Pseudomonas and Aspergillus co-infected cystic fibrosis patients: A UK registry study.
Hughes DA; Archangelidi O; Coates M; Armstrong-James D; Elborn SJ; Carr SB; Davies JC
J Cyst Fibros; 2022 Jan; 21(1):129-135. PubMed ID: 33958279
[TBL] [Abstract][Full Text] [Related]
2. Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.
Reece E; Segurado R; Jackson A; McClean S; Renwick J; Greally P
BMC Pulm Med; 2017 Apr; 17(1):70. PubMed ID: 28431569
[TBL] [Abstract][Full Text] [Related]
3. Change in lung clearance index with microbiological status in children with cystic fibrosis.
Walicka-Serzysko K; Postek M; Milczewska J; Sands D
Pediatr Pulmonol; 2019 Jun; 54(6):729-736. PubMed ID: 30838817
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function.
Düesberg U; Wosniok J; Naehrlich L; Eschenhagen P; Schwarz C
Sci Rep; 2020 Nov; 10(1):18999. PubMed ID: 33149181
[TBL] [Abstract][Full Text] [Related]
5. A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study.
Maliniak ML; Stecenko AA; McCarty NA
J Cyst Fibros; 2016 May; 15(3):350-6. PubMed ID: 26610860
[TBL] [Abstract][Full Text] [Related]
6. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
Walicka-Serzysko K; Sands D
Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
[TBL] [Abstract][Full Text] [Related]
7. Assessing the health risk of living near composting facilities on lung health, fungal and bacterial disease in cystic fibrosis: a UK CF Registry study.
Khan MS; Douglas P; Hansell AL; Simmonds NJ; Piel FB
Environ Health; 2022 Dec; 21(1):130. PubMed ID: 36517903
[TBL] [Abstract][Full Text] [Related]
8. Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.
Pittman JE; Noah H; Calloway HE; Davis SD; Leigh MW; Drumm M; Sagel SD; Accurso FJ; Knowles MR; Sontag MK
PLoS One; 2017; 12(5):e0177215. PubMed ID: 28505188
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis.
Mésinèle J; Ruffin M; Kemgang A; Guillot L; Boëlle PY; Corvol H
J Cyst Fibros; 2022 Jan; 21(1):45-51. PubMed ID: 34629287
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and impact of allergic bronchopulmonary aspergillosis in Pseudomonas aeruginosa-negative CF patients.
De Baets F; De Keyzer L; Van Daele S; Schelstraete P; Van Biervliet S; Van Braeckel E; Thomas M; Wanyama SS
Pediatr Allergy Immunol; 2018 Nov; 29(7):726-731. PubMed ID: 29981532
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
12. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum.
Baxter CG; Rautemaa R; Jones AM; Webb AK; Bull M; Mahenthiralingam E; Denning DW
Thorax; 2013 Jul; 68(7):652-7. PubMed ID: 23513028
[TBL] [Abstract][Full Text] [Related]
13. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.
Jain R; Beckett VV; Konstan MW; Accurso FJ; Burns JL; Mayer-Hamblett N; Milla C; VanDevanter DR; Chmiel JF;
J Cyst Fibros; 2018 Jul; 17(4):484-491. PubMed ID: 29292092
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
Ballmann M; Rabsch P; von der Hardt H
Thorax; 1998 Sep; 53(9):732-7. PubMed ID: 10319054
[TBL] [Abstract][Full Text] [Related]
15. Chronic Pseudomonas aeruginosa infection and respiratory muscle impairment in cystic fibrosis.
Dassios TG; Katelari A; Doudounakis S; Dimitriou G
Respir Care; 2014 Mar; 59(3):363-70. PubMed ID: 23983273
[TBL] [Abstract][Full Text] [Related]
16. The determinants of survival among adults with cystic fibrosis-a cohort study.
Durda-Masny M; Goździk-Spychalska J; John A; Czaiński W; Stróżewska W; Pawłowska N; Wlizło J; Batura-Gabryel H; Szwed A
J Physiol Anthropol; 2021 Nov; 40(1):19. PubMed ID: 34749804
[TBL] [Abstract][Full Text] [Related]
17. Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry.
Vongthilath R; Richaud Thiriez B; Dehillotte C; Lemonnier L; Guillien A; Degano B; Dalphin ML; Dalphin JC; Plésiat P
PLoS One; 2019; 14(1):e0210201. PubMed ID: 30620748
[TBL] [Abstract][Full Text] [Related]
18. Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes.
Limoli DH; Yang J; Khansaheb MK; Helfman B; Peng L; Stecenko AA; Goldberg JB
Eur J Clin Microbiol Infect Dis; 2016 Jun; 35(6):947-53. PubMed ID: 26993289
[TBL] [Abstract][Full Text] [Related]
19. Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis.
Hubert D; Réglier-Poupet H; Sermet-Gaudelus I; Ferroni A; Le Bourgeois M; Burgel PR; Serreau R; Dusser D; Poyart C; Coste J
J Cyst Fibros; 2013 Sep; 12(5):497-503. PubMed ID: 23291443
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.
Kerem E; Viviani L; Zolin A; MacNeill S; Hatziagorou E; Ellemunter H; Drevinek P; Gulmans V; Krivec U; Olesen H;
Eur Respir J; 2014 Jan; 43(1):125-33. PubMed ID: 23598952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
